Clinical Trial Update: Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating erlotinib plus dovitinib (TKI258) in advanced non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dovitinib (dovitinib)
• Tarceva (erlotinib)

Snippet

Sponsor: Heather Wakelee | Conditions: Non-small Cell Lung Cancer (NSCLC), Recurrent, Non-small Cell Lung Cancer (NSCLC), Stage IV | Phase 1 | Status: TERMINATED